Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr
Total income for the period stood at Rs. 7101.28 crore
Total income for the period stood at Rs. 7101.28 crore
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
Subscribe To Our Newsletter & Stay Updated